OCM
FATE icon

Osterweis Capital Management’s Fate Therapeutics FATE Stock Holding History

Osterweis Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-41,605
Closed -$1.03M – 235
2022
Q2 		$1.03M Sell
41,605
-10,850
-21% -$299K 0.08% 108
2022
Q1 		$2.03M Buy
52,455
+8,785
+20% +$340K 0.11% 108
2021
Q4 		$2.56M Sell
43,670
-15,970
-27% -$905K 0.13% 104
2021
Q3 		$3.54M Buy
+59,640
New +$4.68M 0.19% 99

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Osterweis Capital Management's FATE Position: Q3 2022 in Review

Osterweis Capital Management sold out of Fate Therapeutics (FATE) in Q3 2022, closing a stake of 41,605 shares — an estimated $1.03M sold.

Osterweis Capital Management first reported a position in FATE in Q3 2021 and held it in 4 quarters. The position peaked at $3.54M in Q3 2021. 239 funds tracked by Wall St. Rank hold FATE as of Q3 2022.

  • Osterweis Capital Management reported no remaining Fate Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Osterweis Capital Management sold 41,605 Fate Therapeutics shares in Q3 2022, an estimated $1.03M.
  • Osterweis Capital Management first reported a position in Fate Therapeutics in Q3 2021 and held it in 4 quarters.
  • Osterweis Capital Management's Fate Therapeutics position peaked at $3.54M in Q3 2021.
  • 239 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2022.

Based on Osterweis Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.